[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368973-105":59,"doc-detail-368973-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","gastrointestinal-cancer-molecular-pathogenesis-and-targeted-therapy-review-open-access","Gastrointestinal cancer - molecular pathogenesis and targeted therapy - review open access","","Gastrointestinal (GI) cancers drive a major global health burden through complex molecular alterations and bidirectional interactions with the tumor microenvironment. Recurrent driver gene mutations and dysregulated signaling pathways underpin tumor initiation and progression, while epigenetic changes—including DNA hypermethylation, histone modifications, and regulatory non-coding RNAs—reshape chromatin and gene expression. Molecular subtyping using TCGA and CMS clarifies heterogeneity, supports prognostic stratification, and provides biological rationale for diagnostics and targeted interventions. Targeted agents and immunotherapies, including checkpoint inhibition and emerging CAR-T and neoantigen-based approaches, aim to improve outcomes and overcome therapeutic resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/gastrointestinal-cancer-molecular-pathogenesis-and-targeted-therapy-review-open-access/368973/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/gastrointestinal-cancer-molecular-pathogenesis-and-targeted-therapy-review-open-access/368973.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What molecular changes are emphasized in GI cancer pathogenesis?","Question",{"text":112,"@type":113},"The document highlights recurrent driver gene mutations (e.g., KRAS, TP53, APC) and dysregulated signaling pathways such as Wnt, RAS-MAPK, and PI3K-AKT. It also emphasizes epigenetic alterations that change chromatin architecture and gene expression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does molecular subtyping contribute to clinical decision-making?",{"text":117,"@type":113},"It explains that TCGA and CMS classifications reveal disease heterogeneity and enable refined prognostic stratification. These insights support the biological rationale for diagnostics and targeted interventions.",{"name":119,"@type":110,"acceptedAnswer":120},"Which therapeutic strategies are discussed for GI cancers?",{"text":121,"@type":113},"The review covers targeted therapy using anti-EGFR and anti-VEGF monoclonal antibodies, and immunotherapy using checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4. It also describes emerging approaches including CAR-T cell therapy and neoantigen-based vaccines.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368973,1790669309,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":36,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Jin et al. Molecular Biomedicine (2025) 6:136 [https://doi.org/10.1186/s43556-025-00361-9](https://doi.org/10.1186/s43556-025-00361-9)  \nMolecular Biomedicine  \n REVIEW Open Access  \nGastrointestinal cancer: molecular pathogenesis and targeted therapy  \nYang Jin1, Xiaobo He2* andYanfeng Wu2*  \nAbstract  \nGastrointestinal (GI) cancers pose a significant global health burden, driven by complex molecular alterationsand microenvironmental interactions. Advances in molecular pathogenesis have elucidated recurrent driver gene mutations, such as KRAS, TP53, and APC, alongside dysregulated signaling pathways including Wnt, RAS-MAPK, and PI3K-AKT, which collectively underpin tumor initiation and progression. Complementing genetic changes, epigenetic alterations—such as DNA hypermethylation, histone modifications, and regulatory non-coding RNAs—further contribute to malignant evolution by reshaping chromatin architecture and gene expression. These mechanisms not only promote uncontrolled proliferation but also reinforce therapeutic resistance by dynamically modifying the tumor microenvironment (TME) . Molecular subtyping efforts, includingThe Cancer Genome Atlas (TCGA) classification for gastric cancer (GC) and the Consensus Molecular Subtypes (CMS) for colorectal cancer (CRC), have delineated disease heterogeneity, revealing distinct pathogenic pathways and enabling refined prognostic stratification. Such insights provide the biological rationale for diagnostic techniques and targeted interventions. For instance, anti-EGFR and anti-VEGF monoclonal antibodies disrupt oncogenic signaling and tumor angiogenesis, respectively, and have demonstrated substantial clinical efficacy in selected patient populations. In parallel, immunotherapy has emerged as a transformative modality in oncology. Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 reinvigorate antitumor immunity and have reshaped standard-of-care protocols for several GI malignancies. Beyond conventional immunotherapies, innovative strategies such as CAR-T cell therapy and neoantigenbased vaccines are being actively investigated. These approaches aim to overcome immune evasion mechanismsand enhance tumor-specific targeting, offering promise for patients with resistant or advanced disease. This review comprehensively analyzes the evolving molecular landscape of GI cancers and the corresponding development of targeted and immunotherapeutic agents. It highlights a balanced integration of mechanistic discovery and clinical translation, underscoring their synergistic roles in advancing precision oncology and improving survival outcomes. Keywords Gastrointestinal tumors, Immunotherapy, Targeted Therapy, Signal Transduction  \n*Correspondence: Xiaobo He[hexiaobo@immunol.org](hexiaobo@immunol.org)[ ](hexiaobo@immunol.org)Yanfeng Wu [wuyf@immunol.org](wuyf@immunol.org)  \n1 College of Basic Medical Sciences, Naval Medical University, Shanghai 200433, People’s Republic of China  \n2 National Key Laboratory of Immunity and Inflammation & Institute of Immunology, College of Basic Medical Sciences, Naval Medical University, Shanghai 200433, People’s Republic of China  \nIntroduction  \nGastrointestinal (GI) cancers represent a significant global health challenge, with approximately 4.8 million new cases and 3.4 million deaths annually, making them one of the leading causes of cancer-related mortality. A deeper understanding of their underlying molecular mechanisms, including driver genes, signaling pathways, and the tumor microenvironment (TME), is therefore crucial for laying the foundation to develop more effective therapeutic regimens.  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and ind","cbCaioDhhii7se9F","https://ap.wps.com/l/cbCaioDhhii7se9F","pdf",5408994,"English","# Abstract\n# Introduction\n## Global burden and need for molecular understanding\n## Precision medicine phases in GI cancers","[{\"question\":\"What molecular changes are emphasized in GI cancer pathogenesis?\",\"answer\":\"The document highlights recurrent driver gene mutations (e.g., KRAS, TP53, APC) and dysregulated signaling pathways such as Wnt, RAS-MAPK, and PI3K-AKT. It also emphasizes epigenetic alterations that change chromatin architecture and gene expression.\"},{\"question\":\"How does molecular subtyping contribute to clinical decision-making?\",\"answer\":\"It explains that TCGA and CMS classifications reveal disease heterogeneity and enable refined prognostic stratification. These insights support the biological rationale for diagnostics and targeted interventions.\"},{\"question\":\"Which therapeutic strategies are discussed for GI cancers?\",\"answer\":\"The review covers targeted therapy using anti-EGFR and anti-VEGF monoclonal antibodies, and immunotherapy using checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4. It also describes emerging approaches including CAR-T cell therapy and neoantigen-based vaccines.\"}]","Gastrointestinal cancer - molecular pathogenesis and targeted therapy - review open access | PDF",1790179983,101,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26ef802165b31e7548a833eda94dbe54.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7449a523eae9cd03725bfab56da5d14d.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5fb2715fa4c884b514c4e05ecff614ce.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6542392a0f0d39a4df5df28995febc76.webp",980,1301]